Mer

Home / APOQUEL

APOQUEL

INDICATIONS

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Do not use APOQUEL® in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

Reference: 2. Cosgrove SB, Wren JA, Cleaver DM. et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114.

IMPORTANT NOTICE!

Please note that this is a general product information according to US approvals, for specific regulatory information concerning your market please contact Regulatory department email: Regulatory.AffairsMER@zoetis.com

Close

Expand All
  • Dosing & Adminstration

     

    • The dose of APOQUEL tablets is 0.18 to 0.27 mg/lb (0.4 to 0.6 mg/kg)
    • APOQUEL should be given twice daily for up to 14 days of therapy and
      once daily thereafter for maintenance
    • APOQUEL may be given with or without food
    • APOQUEL may be used concomitantly with many common therapies including vaccines, NSAIDs, antibiotics and allergen immunotherapy3

    Prescribing Information

     

     

  • Questions About US Supply

    • IN THE PAST, ZOETIS ANNOUNCED INCREASED AVAILABILITY FOR APOQUEL AND ALMOST IMMEDIATELY LIMITED SUPPLY AGAIN; HOW CAN WE BELIEVE APOQUEL WILL CONTINUE TO BE AVAILABLE?
    • Zoetis recognizes the frustration veterinarians and their clients have faced because of our past supply challenges. As we implemented a scaled up manufacturing process to address the true demand for APOQUEL, we encountered new challenges in the process. Since then, our Global Manufacturing and Supply team has worked diligently to address consistency issues with certain ingredients and refine manufacturing specifications. Those issues have now been resolved
    • WHAT STEPS DID ZOETIS TAKE TO ADDRESS THESE CHALLENGES?
    • Zoetis has made widespread efforts and investments to address manufacturing issues and increase the supply of APOQUEL for the long term. We have:
      • Doubled the number of suppliers for the raw material to make APOQUEL
      • Doubled the number of facilities manufacturing APOQUEL
      • Streamlined the manufacturing process and invested in new equipment to make the process faster than before
    • WHAT IS THE ZOETIS POLICY ON DIVERSION?
    • Zoetis takes diversion very seriously. We are committed to serving the veterinary profession and providing customers with innovative products, services and solutions to enhance the care and well-being of the pets under their care. That is why APOQUEL orders are constantly reviewed to detect and prevent diversion of product.

      Our business philosophy is driven by our Commitment to Veterinarians™ platform, which recognizes and advocates for the role of veterinarians in a direct relationship with their clients and patients.

      To view the Zoetis policy on diversion, please click here.